Asston Pharmaceuticals Limited, a prominent player in the pharmaceutical sector, has announced a series of strategic moves aimed at strengthening its corporate structure and facilitating growth. The company's board of directors approved several key appointments and funding arrangements in a meeting held on October 16, 2025.

Leadership Appointments

The board has made significant additions to its leadership team:

1. Mr. Yogesh Supekar has been appointed as an Additional Non-Executive Non-Independent Director. With an MBA in Finance and 24 years of experience across banking, media, and public relations, Mr. Supekar brings a wealth of financial acumen to the board.

2. Mr. Rishi Upadhaya joins as the new Company Secretary and Compliance Officer. Mr. Upadhaya, aged 28, is a qualified Company Secretary with a strong academic background in commerce and is currently pursuing an LLB.

3. M/s Yash A. Jain & Associates has been appointed as the internal auditor for the fiscal year 2025-2026. Led by CA Yash Jain, the firm brings over 5 years of expertise in corporate advisory, audit, assurance, and tax services.

Funding Initiatives

Asston Pharmaceuticals has also secured significant funding to support its growth plans:

1. The board has approved an interest-free unsecured loan of up to Rs 3.00 crore from the company's directors. This loan can be introduced either as a lump sum or in tranches.

2. A secured loan facility of up to Rs 2.70 crore from HDFC Bank has been approved for the purchase of commercial space. The loan will be secured against the property to be acquired.

Financial Implications

These financial moves indicate Asston Pharmaceuticals' commitment to expansion and operational enhancement. The interest-free loan from directors showcases their confidence in the company's future prospects.

Compliance and Governance

All appointments have been made in compliance with regulatory requirements. Notably, Mr. Yogesh Supekar is not debarred from holding a directorship by any SEBI or other regulatory order. The company has affirmed that none of the new appointees are related to existing directors, ensuring independence in decision-making.

These strategic decisions by Asston Pharmaceuticals suggest a focus on strengthening corporate governance, enhancing financial capabilities, and laying the groundwork for future growth in the pharmaceutical sector.

Asston Pharmaceuticals Limited, a pharmaceutical company based in Navi Mumbai, Maharashtra, has announced significant changes in its key personnel. Both the Chief Financial Officer (CFO) and the Company Secretary and Compliance Officer have resigned from their positions.

CFO Resignation

Deven Manohar Patil has stepped down from his role as Chief Financial Officer of Asston Pharmaceuticals Limited. His resignation was effective October 13, 2025, with his last working day being at the close of business hours on the same date. Mr. Patil cited the pursuit of new career opportunities outside the company as the reason for his departure. The Board of Directors received his resignation letter on October 13, 2025.

Company Secretary Resignation

In addition to the CFO's departure, Mrs. Vandana Mishra, who held the position of Company Secretary and Compliance Officer (membership number A64684), has also resigned. Her resignation was effective immediately, with her last working day also being October 13, 2025, at the close of business hours. Like Mr. Patil, Mrs. Mishra is leaving to pursue new career opportunities outside the company.

Company's Response

Saili Jayaram More, Whole Time Director of Asston Pharmaceuticals, filed regulatory disclosures to inform stakeholders of these changes. In compliance with SEBI regulations, specifically Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company provided the following details for Mrs. Mishra's resignation:

Impact and Next Steps

The simultaneous departure of both the CFO and the Company Secretary and Compliance Officer represents a significant change in Asston Pharmaceuticals' leadership team. These roles are crucial for financial management, regulatory compliance, and maintaining good corporate governance practices.

Asston Pharmaceuticals Limited will likely be in the process of finding suitable replacements to fill these important positions. The company has not yet announced any information regarding successors for either Mr. Patil or Mrs. Mishra.

Investors and stakeholders will be watching closely to see how quickly Asston Pharmaceuticals can fill these key roles and ensure a smooth transition in its financial, compliance, and secretarial functions.